Display options
Cite
Woods LT, Jasmer KJ, Muñoz Forti K, et al. P2Y. Oral Oncol. 2020;109:104808doi: 10.1016/j.oraloncology.2020.104808.
Woods, L. T., Jasmer, K. J., Muñoz Forti, K., Shanbhag, V. C., Camden, J. M., Erb, L., Petris, M. J., & Weisman, G. A. (2020). P2Y. Oral oncology, 109104808. https://doi.org/10.1016/j.oraloncology.2020.104808
Woods, Lucas T, et al. "P2Y." Oral oncology vol. 109 (2020): 104808. doi: https://doi.org/10.1016/j.oraloncology.2020.104808
Woods LT, Jasmer KJ, Muñoz Forti K, Shanbhag VC, Camden JM, Erb L, Petris MJ, Weisman GA. P2Y. Oral Oncol. 2020 Jun 12;109:104808. doi: 10.1016/j.oraloncology.2020.104808. Epub 2020 Jun 12. PMID: 32540611; PMCID: PMC7736485.
Copy Download .nbib Format: NLM
Share it on

Oral Oncol. 2020 Jun 12;109:104808. doi: 10.1016/j.oraloncology.2020.104808. Epub 2020 Jun 12.

P2Y.

Oral oncology

Lucas T Woods, Kimberly J Jasmer, Kevin Muñoz Forti, Vinit C Shanbhag, Jean M Camden, Laurie Erb, Michael J Petris, Gary A Weisman

Affiliations

  1. Division of Biochemistry, University of Missouri, Columbia, MO 65211-7310 USA; Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, MO 65211-7310 USA.
  2. Division of Biochemistry, University of Missouri, Columbia, MO 65211-7310 USA; Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, MO 65211-7310 USA; Department of Ophthalmology, University of Missouri School of Medicine, Columbia, MO 65211-7310 USA.
  3. Division of Biochemistry, University of Missouri, Columbia, MO 65211-7310 USA; Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, MO 65211-7310 USA. Electronic address: [email protected].

PMID: 32540611 PMCID: PMC7736485 DOI: 10.1016/j.oraloncology.2020.104808

Abstract

OBJECTIVES: To assess functional expression of the P2Y

MATERIALS AND METHODS: In human HNSCC cell lines CAL27 and FaDu and the mouse oral cancer cell line MOC2, P2Y

RESULTS: P2Y

CONCLUSION: P2Y

Copyright © 2020 Elsevier Ltd. All rights reserved.

Keywords: Adenosine 5′-Triphosphate; Cetuximab; Epidermal Growth Factor Receptor; Head and Neck Squamous Cell Carcinoma; Purinergic P2Y(2) Receptor Antagonist; Purinergic P2Y(2) Receptors; Tumor Microenvironment

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this pa

References

  1. Am J Physiol Cell Physiol. 2014 Jul 1;307(1):C83-96 - PubMed
  2. PLoS One. 2008 Jul 09;3(7):e2599 - PubMed
  3. Mol Cancer. 2014 May 08;13:105 - PubMed
  4. Carcinogenesis. 2014 Jun;35(6):1238-47 - PubMed
  5. PLoS One. 2010 Sep 13;5(9):e12702 - PubMed
  6. J Cell Physiol. 2001 May;187(2):196-208 - PubMed
  7. J Cell Physiol. 1984 Feb;118(2):124-32 - PubMed
  8. PLoS One. 2015 Jul 16;10(7):e0133165 - PubMed
  9. J Biol Chem. 2005 May 13;280(19):18696-702 - PubMed
  10. Mol Cancer Ther. 2007 Apr;6(4):1414-24 - PubMed
  11. J Int Med Res. 2016 Dec;44(6):1234-1247 - PubMed
  12. Mol Cancer Res. 2017 Dec;15(12):1667-1677 - PubMed
  13. Int J Cancer. 2012 Jan 1;130(1):40-7 - PubMed
  14. J Biol Chem. 2010 Mar 5;285(10):7545-55 - PubMed
  15. Am J Cancer Res. 2016 Sep 01;6(9):1963-1975 - PubMed
  16. J Biol Chem. 1998 Sep 4;273(36):23110-7 - PubMed
  17. Cancer Res. 1993 Aug 1;53(15):3579-84 - PubMed
  18. Clin Cancer Res. 2011 Aug 1;17(15):4996-5004 - PubMed
  19. Cancer Res. 2006 Dec 15;66(24):11831-9 - PubMed
  20. Oncologist. 2013;18(7):850-64 - PubMed
  21. Clin Cancer Res. 2019 Feb 15;25(4):1318-1330 - PubMed
  22. Wiley Interdiscip Rev Membr Transp Signal. 2012 Nov-Dec;1(6):789-803 - PubMed
  23. J Biol Chem. 2014 Jul 4;289(27):19137-49 - PubMed
  24. Biochim Biophys Acta. 1992 Feb 19;1134(1):61-72 - PubMed
  25. Cancer Res. 2004 Sep 1;64(17):6166-73 - PubMed
  26. Cancer Cell. 2005 Apr;7(4):301-11 - PubMed
  27. Mol Immunol. 2008 Jan;45(1):65-75 - PubMed
  28. J Biol Chem. 1998 Jan 30;273(5):2653-60 - PubMed
  29. EMBO J. 2003 May 15;22(10):2411-21 - PubMed
  30. Cancer. 2008 Jun 15;112(12):2710-9 - PubMed
  31. Eur J Cell Biol. 2012 Jun-Jul;91(6-7):472-85 - PubMed
  32. Oral Dis. 2018 Jul;24(5):761-771 - PubMed
  33. Oncol Rep. 2018 Jan;39(1):138-150 - PubMed
  34. J Biol Chem. 2004 Aug 20;279(34):35679-86 - PubMed
  35. J Cancer. 2017 Feb 25;8(5):761-773 - PubMed
  36. Nat Rev Cancer. 2018 May;18(5):269-282 - PubMed
  37. Cancer Res. 2012 Jan 1;72(1):365-74 - PubMed
  38. Oral Maxillofac Surg Clin North Am. 2014 May;26(2):123-41 - PubMed
  39. Am J Respir Cell Mol Biol. 2004 Oct;31(4):446-55 - PubMed
  40. Emerg Infect Dis. 2010 Nov;16(11):1671-7 - PubMed
  41. Oncotarget. 2017 Mar 17;8(33):55600-55612 - PubMed
  42. Nat Rev Cancer. 2018 Oct;18(10):601-618 - PubMed
  43. Front Pharmacol. 2019 Jun 13;10:612 - PubMed
  44. Proc Natl Acad Sci U S A. 2006 May 2;103(18):6901-6 - PubMed
  45. Physiol Rev. 2002 Oct;82(4):1013-67 - PubMed
  46. Int J Mol Sci. 2019 Feb 15;20(4): - PubMed
  47. Cancer Sci. 2017 Jul;108(7):1318-1327 - PubMed
  48. J Biol Chem. 2004 Feb 27;279(9):8212-8 - PubMed
  49. Breast Cancer Res. 2014 Aug 26;16(5):R77 - PubMed
  50. Oncogene. 2008 Jun 26;27(28):3944-56 - PubMed
  51. Otolaryngol Head Neck Surg. 2012 Sep;147(3):493-500 - PubMed
  52. Oncotarget. 2015 Nov 3;6(34):36400-17 - PubMed
  53. Oncogene. 2003 Sep 18;22(40):6183-93 - PubMed
  54. Oncotarget. 2014 Oct 15;5(19):9322-34 - PubMed
  55. Auton Autacoid Pharmacol. 2007 Apr;27(2):79-84 - PubMed
  56. Purinergic Signal. 2017 Mar;13(1):89-103 - PubMed
  57. Pancreas. 2013 May;42(4):680-6 - PubMed
  58. Expert Rev Anticancer Ther. 2018 Sep;18(9):901-915 - PubMed

Publication Types

Grant support